Similar articles

• The relative clinical effectiveness of HFA-BDP and fluticasone propionate in asthma.

  Fairfax AJ. Fairfax AJ. Respir Med. 2000 Sep;94 Suppl D:S31-6. doi: 10.1016/s0954-6111(00)90122-7. Respir Med. 2000. PMID: 11003173 Review. No abstract available.
• A comparison of HFA-BDP Autohaler with budesonide Turbuhaler in asthma control of adult patients with mild to moderately severe disease.

  Worth H. Worth H. Respir Med. 2000 Sep;94 Suppl D:S27-30. doi: 10.1016/s0954-6111(00)90121-5. Respir Med. 2000. PMID: 11003172 Review. No abstract available.
• The comparative safety/efficacy ratio of HFA-BDP.

  Lipworth BJ. Lipworth BJ. Respir Med. 2000 Sep;94 Suppl D:S21-6. doi: 10.1016/s0954-6111(00)90120-3. Respir Med. 2000. PMID: 11003171 Review.
• HFA-BDP and its implications for the quiet zone.

  Tashkin DP. Tashkin DP. Respir Med. 2000 Sep;94 Suppl D:S37-9. doi: 10.1016/s0954-6111(00)90123-9. Respir Med. 2000. PMID: 11003174 Review. No abstract available.
• Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children.

  Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Van Essen-Zandvliet E, Arora S, Szefler SJ; Pediatric Study Group. Pedersen S, et al. Pediatrics. 2002 Jun;109(6):e92. doi: 10.1542/peds.109.6.e92. Pediatrics. 2002. PMID: 12042586 Clinical Trial.